Clinical Trials Logo

Wound of Skin clinical trials

View clinical trials related to Wound of Skin.

Filter by:

NCT ID: NCT06178289 Recruiting - Wound of Skin Clinical Trials

The Effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the Treatment of Moisture-associated Skin Damage in Nursing Homes

ISR-CASP-MASD
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Objectives: The aim of this study is to evaluate the effectiveness of 3M™ Cavilon™ Advanced Skin Protectant in the treatment of partial-thickness wounds caused by moisture (MASD) compared to usual wound care treatment in Belgian nursing homes. Methodology: RESEARCH DESIGN: A randomized controlled multicentre clinical trial. DATA COLLECTION: Randomization/Blinding and Participant Numbering: The patients will be allocated 1:1 by block randomization, using the REDCap Randomization Module, to either Cavilon™ Advanced Skin Protectant or local nursing home partial-thickness wound (MASD) treatment protocol, yielding one study group. Due to the obvious differences between the comparative nursing home wound care treatment products and the study device, the study nurses cannot be blinded. A blinded assessor will centrally assess the time to healing and other healing outcomes based on the photographs of the study area. Study area: Defined as all partial-thickness, skin damaged areas on the body - due to exposure to (a) incontinence body fluids, (b) wound exudate, (c) stomal- or fistula effluent or digestive secretions. Study duration: 21 days or until complete healing of the moisture associated skin damage (complete epithelialization). Skin (MASD) assessment: Daily skin assessment of the study area is to be conducted by the study nurses. Relevant wound and patient information will be recorded (incontinence status, presence of a urinary catheter or faecal management system, number of absorbent pad or diaper changes, number of cleansing procedures, type of stoma, number of applications regarding Cavilon Advanced Skin Protectant or usual nursing home wound treatment protocol). Digital planimetry software (PictZar® version 7.6.1 ss) will be the main mode of assessing wound healing. Therefore, daily photographs will be taken with each daily skin assessment after removal of all visual product to ensure blinded skin assessment by the central reviewer. Pain assessment: The Wong-Baker FACES® Pain Rating Scale will be used to assess pain daily. Treatment-related pain (pain experienced during treatment (cleansing and product application)) and wound related pain (pain perception specifically caused by the MASD lesion) will be assessed. Nursing time assessment: Time per cleansing and time per treatment application.

NCT ID: NCT05844527 Recruiting - Wound of Skin Clinical Trials

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.

NCT ID: NCT05797688 Withdrawn - Wound of Skin Clinical Trials

Adipose-derived Stem Cells to Treat Chronic Wounds.

Start date: December 2016
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine whether autologous, adipose-derived regenerative cells improve the healing of chronic wounds. Ten patients will undergo fat harvest and peri-wound injection of the isolated cells in addition to the standard of care for the treatment of their chronic wound. Wound healing will be followed over 24 weeks.

NCT ID: NCT05741866 Recruiting - Wound Infection Clinical Trials

Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs)

ProP
Start date: May 3, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare a chlorhexidine impregnated dressing for peripheral intravenous catheters (PIVCs) to the standard dressing currently used in general medical and surgical inpatient wards. The main questions it aims to answer are: - Study Feasibility - Occurrence of infectious complications related to the PIVC Participants will be randomly allocated to receive either of the below dressings to cover and secure their PIVC: - The standard dressing used at their hospital, or - The intervention dressing which has Chlorhexidine gluconate (CHG) on it Researchers will compare standard and CHG dressings to see if the presence of CHG improves the occurrence of infectious complications related to the PIVC.

NCT ID: NCT05727995 Recruiting - Wound of Skin Clinical Trials

Efficacy of Prophylactic Negative Pressure Wound Therapy (NPWT)

EFESO
Start date: July 25, 2019
Phase: N/A
Study type: Interventional

The role of prophylactic negative pressure wound therapy (NPWT) is promising in reducing wound-related complications. However, the prophylactic use of NPWT in reducing wound complications in patients who underwent conventional open harvesting of the great saphenous vein has been under-investigated compering with other surgical approaches. Therefore, this study aims to assess the effect size of the prophylactic NPWT in preventing wound dehiscence in high-risk patients who underwent conventional open harvesting of the great saphenous vein as a conduit for coronary artery bypass.

NCT ID: NCT05618912 Recruiting - Clinical trials for Patient Satisfaction

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

Start date: October 17, 2022
Phase: N/A
Study type: Interventional

Patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. After closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days(Experimental) or the standard dressing (Control) that will be covered with petrolatum jelly and bandaging during this time period, which has to be re-applied daily. Patients and dermatologic surgeons will then complete surveys 7 days, 30 days, and 90 days after surgery to evaluate the cosmetic appearance of these scars.

NCT ID: NCT05608317 Recruiting - Venous Leg Ulcer Clinical Trials

A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing

Start date: November 8, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit. Participants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.

NCT ID: NCT05588583 Recruiting - Diabetic Foot Ulcer Clinical Trials

A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.

Start date: October 31, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit. Participants will be asked to wear Mepilex Up dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.

NCT ID: NCT05462860 Not yet recruiting - Burns Clinical Trials

Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to SoC.

NCT ID: NCT05378997 Completed - Clinical trials for Epidermolysis Bullosa

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

Start date: April 7, 2022
Phase: Phase 1
Study type: Interventional

This is a three-part, Phase I, first-in-human study designed to evaluate the safety, tolerability, and potential systemic exposure of multiple topical doses of TCP-25. Part I includes healthy volunteers with acute epidermal wounds formed by the suction blister technique. Part II includes patients with non-healing leg ulcers and Part III patients with dystrophic epidermolysis bullosa (DEB).